Retifanlimab Plus Carboplatin and Paclitaxel Improve PFS in Recurrent/Metastatic Anal Cancer

September 15, 2024

Retifanlimab plus carboplatin and paclitaxel improved progression-free survival for recurrent or metastatic SCAC, according to the phase 3 POD1UM-303/InterAACT 2 study.

Related Clinical Trials

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Reference News

nursing.onclive.com

Retifanlimab Plus Carboplatin and Paclitaxel Improve PFS in Recurrent/Metastatic Anal Cancer

Retifanlimab plus carboplatin and paclitaxel improved progression-free survival for recurrent or metastatic SCAC, according to the phase 3 POD1UM-303/InterAACT 2 study.